Yohei Yamauchi

Yohei Yamauchi

Auto-generated profile, based on publicly available information

Yohei Yamauchi

Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
SFShimpei Fujioka
Shimpei Fujioka
DSDaisuke Shishikura
Daisuke Shishikura
HKHirofumi Kusumoto
Hirofumi Kusumoto
YYYohei Yamauchi
Yohei Yamauchi
KSKazushi Sakane
Kazushi Sakane
MHMasaaki Hoshiga
Masaaki Hoshiga
Current guidelines advocate achieving a fixed LDL-C target and ≥50% reduction in LDL-C levels. However, sufficient LDL-C reduction is often not achieved even in patients achieving a fixed LDL-C target. This study investigated the clinical impact of insufficient LDL-C reduction following lipid lowering therapy on cardiovascular outcomes acute coronary syndrome (ACS) patients. A total of 561 consecutive ACS patients who had undergone PCI and LDL-C level measurement at index PCI and 12 months afterwards were evaluated retrospectively. we investigated a relationship between ≥50% LDL-C reduction and cardiovascular events including the composite of cardiac death, myocardial infarction, target vessel revascularization and stent thrombosis. Of the patients, 145 (25.8%) achieved ≥50% LDL-C reduction within 12 months. There were no significant differences in cardiovascular events between patients achieving the LDL-C target of 55 mg/dL and those not achieving it (23.6% vs 19.3%, P = .77), whereas the incidence of cardiovascular events was higher in the <50% LDL-C reduction group than the ≥50% LDL-C reduction group (26.0% vs 12.4%, P = .009). Even in patients with LDL-C < 55 mg/d/L, cardiovascular events were more frequently in the <50% LDL-C reduction group than the ≥50% LDL-C reduction group (28.8% vs 13.2%, P = .04). Cox proportional hazard models revealed that <50% LDL-C reduction was an independent predictor of cardiovascular outcomes (HR: 2.03, 95% CI: 1.23-3.36). The current study underscores the significance of achieving ≥50% LDL-C reduction in addition to a target of 55 mg/dL in preventing additional cardiovascular events in ACS patients.

5 January 2025 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
DSDaisuke Shishikura
Daisuke Shishikura
YKYu Kataoka
Yu Kataoka
SNStephen J. Nicholls
Stephen J. Nicholls
KRKausik K. Ray
Kausik K. Ray
RPRishi Puri
Rishi Puri
MHMasaaki Hoshiga
Masaaki Hoshiga
The ongoing residual cardiovascular risks despite lowering low-density lipoprotein cholesterol (LDL-C) levels suggest the need to identify additional drivers associated with atherosclerosis. Circulating lipoprotein(a) [Lp(a)]promotes formation of foam cells via its proatherogenic properties. However, whether a lower Lp(a) level in combination with favorable LDL-C control could induce a more stable form of disease remains unknown. Near-infrared spectroscopy (NIRS) generates maximum lipid-core burden index in 4 mm (MaxLCBI4 mm) which is a histologically validated measure of lipidic plaque material in vivo. Therefore, the current study employed NIRS imaging to characterize lipidic plaque in association with LDL-C < 70 mg/dL and Lp(a) <50 mg/dL. We analyzed 439 patients with coronary artery disease (CAD) (554 de-novo target lesions receiving percutaneous coronary intervention) in the REASSURE-NIRS registry (NCT04864171). Clinical characteristics and NIRS-derived MaxLCBI4mm were compared among 4 groups according to LDL-C of 70 mg/dL and Lp(a) of 50 mg/dL. Almost one-third of study subjects (33.4%) exhibited both LDL-C < 70 mg/dL and Lp(a) <50 mg/dL. They were more likely male with a lower frequency of acute coronary syndrome and lipid lowering therapies were more frequently used in those with LDL-C < 70 mg/dL and Lp(a) <50 mg/dL. On NIRS imaging analysis, a smaller MaxLCBI4mm (P < .001) and a lower frequency of MaxLCBI4mm ≥400 (P = .001) were observed in those with both LDL-C < 70 mg/dL and Lp(a) <50 mg/dL. On multivariable logistic regression analysis, the coexistence of these 2 lipid controls showed an approximately 70% lower risk (adjusted odds ratio: 0.30; 95% confidence interval: 0.13-0.68) of MaxLCBI4mm ≥400 compared with the reference group (LDL-C ≥ 70 mg/dL and Lp(a) ≥50 mg/dL). Our findings suggest circulating Lp(a) as a potential therapeutic target to stabilize coronary atherosclerosis in CAD patients who achieved LDL-C < 70 mg/dL.

6 July 2026 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
MHMinju Han
Minju Han
JCJaewook Chung
Jaewook Chung
SYSeokhun Yang
Seokhun Yang
SPSang-Hyeon Park
Sang-Hyeon Park
JZJinlong Zhang
Jinlong Zhang
BKBon-Kwon Koo
Bon-Kwon Koo